AJU-S56

AJU-S56 is an investigational intraocular therapeutic being developed for the treatment of dry eye disease, including moderate to severe dry eye syndrome and Sjogren's syndrome. It is currently in phase 3 clinical trials, where it is administered as a 5% ophthalmic solution and compared to vehicle (placebo) in adult patients. The drug is being developed by AJU Pharm, a South Korean pharmaceutical company. While the precise mechanism of action has not been publicly disclosed, its development focuses on improving symptoms and signs associated with dry eye conditions.

Other names

7-carboxymethyloxy-3',4',5-trimethoxy flavone7-carboxymethyloxy-3',4',5-trimethoxy flavone monohydrate